Key Highlights
- Aclaris Therapeutics (NASDAQ:ACRS) rose 7.46% pre-market to a listed USD 3.60 on 1,051 shares, with a market capitalization of USD 530 million and an RSI of 29.5 labeled Down, oversold.
- Aclaris reported a second-quarter net loss of USD 21.5 million, cash of USD 170.6 million and an extra USD 40.2 million from at-the-market sales, with a runway it expects to last through 2028.
- Its ATI-052 bispecific antibody showed favorable safety and potential for quarterly dosing in a Phase 1a trial, and Phase 1b results in asthma and atopic dermatitis are due in the second half.
- Bosakitug, an anti-TSLP antibody tested in 109 atopic dermatitis patients, reads out in the fourth quarter, while the stock rose 7.46% on only 1,051 shares at an oversold RSI of 29.5.
The Latest Verified Updates
No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. Aclaris reported second-quarter 2026 results on August 6, with a net loss of USD 21.5 million versus USD 15.4 million a year earlier and revenue of USD 1.6 million. Full Phase 1a results for ATI-052, an anti-TSLP and IL-4 receptor alpha bispecific antibody, showed it was well tolerated with strong, sustained pharmacokinetics and pharmacodynamics supporting up to quarterly dosing. The company plans a Phase 2b program for ATI-052, starting with asthma in the fourth quarter of 2026, plus startup work for atopic dermatitis and an eosinophilic esophagitis proof-of-concept trial.
The Data Behind the Move
Cash, cash equivalents and marketable securities were USD 170.6 million at June 30, and at-the-market sales since then added USD 40.2 million in gross proceeds, which extends the runway through 2028. Three readouts are expected: placebo-controlled Phase 1b results for ATI-052 in asthma and atopic dermatitis in the second half of 2026, and a fourth-quarter Phase 2 result for bosakitug in 109 atopic dermatitis patients. Net cash used in operations was USD 38.0 million in the first half versus USD 23.1 million a year earlier, so the burn rate is rising as trials expand. If the listed price is the pre-market quote, simple arithmetic puts the prior close near USD 3.35; if it is the last close, the implied pre-market price is near USD 3.87, so check a live quote. Pre-market traded value is only about USD 0.00 million, a tiny slice of the company's size, so few dollars set the price. Volume of 1,051 shares is thin, under 10,000 shares, and the screener tag reads No catalyst found, which classifies the catalyst and does not set direction.
Risks and What to Watch
Three binary data readouts and recurring at-the-market sales make the stock sensitive to both results and dilution. What to watch next: the ATI-052 Phase 1b results and the bosakitug Phase 2 readout. This is information only and not investment advice.
Where Things Stand
Market conditions frame the day: futures were muted as big banks report, the Kospi fell 5.5% and chip and memory stocks were under pressure. Aclaris Therapeutics (NASDAQ:ACRS) is moving with an oversold bounce ahead of three clinical readouts. A pre-market gain on this volume can reverse once regular trading opens, so the balance of evidence favors waiting for confirmation from filings and the open. Direction remains unknown, and the next catalyst is the ATI-052 Phase 1b results and the bosakitug Phase 2 readout. Check the underlying filings first, verify the latest filings before acting, and treat the figures as a snapshot.






Please wait processing your request...